the effect of biofeedback therapy on dyssynergic constipation in patients with or without irritable bowel syndrome

نویسندگان

tannaz ahadi

faezeh madjlesi

bahar mahjoubi

rezvan mirzaei

چکیده

background: the rome ii and iii diagnostic criteria for dyssynergic defecation recommended the exclusion of irritable bowel syndrome (ibs). this study determined the effect of biofeedback therapy on dyssynergic constipation in patients with or without  irritable bowel syndrome. materials and methods: this study was a non-randomized, single blinded, semi experimental study. dyssynergic defecation patients with and without ibs were asked to undergo biofeedback therapy 8 sessions. the defecation dynamics and balloon expulsion time were evaluated before, at the end and one month after the biofeedback therapy. ibs symptoms were graded using a 4-point likert scale. mann-whitney u test, wilcoxon test and friedman test were applied to analyse data by spss software package.results: after the biofeedback therapy, the ibs symptoms have been decreased significantly (the median of 2 before and 1 after therapy, p<0.01). the biofeedback therapy significantly decreased the anismus index in ibs group by the mean of 0.75±0.31, 0.28±0.07and 0.28±0.06 in three phases, respectively. similar results were found in non-ibs patients (the mean of 0.74±0.32, 0.28±0.08, 0.27±0.08 in three phases, respectively). the symptoms of constipation (sensation of incomplete evacuation, difficult and painful defecation), defecation facilitative manual maneuver frequency, pelvic floor muscles resting amplitude and strain amplitude decreased  and squeezing amplitude improved significantly after biofeedback therapy in both groups with and without ibs (p<0.001). there were not significant differences between patients with and without ibs (p>0.05) with respect to outcome. no complication was observed in treatment groups. conclusion: dyssynergic constipation patients with and without ibs will likely benefit from biofeedback therapy.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The effect of biofeedback therapy on dyssynergic constipation in patients with or without Irritable Bowel Syndrome

BACKGROUND The Rome II and III diagnostic criteria for dyssynergic defecation recommended the exclusion of irritable bowel syndrome (IBS). This study determined the effect of biofeedback therapy on dyssynergic constipation in patients with or without IBS. MATERIALS AND METHODS This study was a nonrandomized, single blinded, semi experimental study. Dyssynergic defecation patients with and wit...

متن کامل

Outcome of biofeedback therapy in dyssynergic defecation patients with and without irritable bowel syndrome.

AIM The Rome II and III diagnostic criteria for dyssynergic defecation require the exclusion of irritable bowel syndrome (IBS). To prospectively study whether the presence of IBS affects the outcome of biofeedback therapy in dyssynergic defecation patients. METHODS Consecutive patients with dyssynergic defecation underwent biofeedback therapy. Dyssynergic defecation was diagnosed based on sym...

متن کامل

Rifaximin therapy for patients with irritable bowel syndrome without constipation.

BACKGROUND Evidence suggests that gut flora may play an important role in the pathophysiology of the irritable bowel syndrome (IBS). We evaluated rifaximin, a minimally absorbed antibiotic, as treatment for IBS. METHODS In two identically designed, phase 3, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2), patients who had IBS without constipation were randomly assigned to eith...

متن کامل

The Effect of Written Expression on Severity of Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome

Background & Aims: Irritable Bowel Syndrome (IBS) is one of the most common gastrointestinal disorders that significantly affects patients' quality of life. This study aimed to determine the effect of written expression on the severity of gastrointestinal symptoms in patients with IBS.  Materials & Methods: This clinical trial study was conducted in 2019 on 71 patients with IBS who were referr...

متن کامل

Safety and efficacy of tegaserod therapy in patients with irritable bowel syndrome or chronic constipation.

BACKGROUND Tegaserod, a 5-HT4 agonist, is effective for treating irritable bowel syndrome and chronic constipation. However, sales of this drug were recently suspended due to concerns about a higher rate of cardiovascular events in patients receiving tegaserod over placebo in clinical trials. Our aim was to review patients in our practice prescribed tegaserod to determine if any of them had suf...

متن کامل

Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.

BACKGROUND AND AIMS Tegaserod is approved for the treatment of constipation-predominant irritable bowel syndrome (C-IBS) in females. The aim of this study was to evaluate the effect of tegaserod on colonic transit time (CTT) and symptoms in male patients with C-IBS. METHODS Forty-four males with C-IBS (Rome II) were enrolled. After a baseline washout period of 2 weeks, 40 patients were random...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
journal of research in medical sciences

جلد ۱۹، شماره ۱۰، صفحات ۰-۰

کلمات کلیدی

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023